公开(公告)号：US20160159878A1

公开(公告)日：2016-06-09

申请号：US14952613

申请日：2015-11-25

Applicant: Biogen MA Inc.

Inventor： Daniel H.S. Lee ,  Dingyi Wen ,  R. Blake Pepinsky ,  Jane K. Relton ,  Xinzhong Wang ,  Alexey Lugovskoy ,  Werner Meier ,  Ellen A. Garber ,  Laura Silvian ,  Paul H. Weinreb

IPC: C07K14/705

CPC classification number: C07K14/705 ,  A01K67/027 ,  A01K67/0275 ,  A01K2217/058 ,  A01K2227/105 ,  A01K2267/0356 ,  A61K38/179 ,  A61K39/3955 ,  A61K48/00 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2863 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/33 ,  C07K2319/74 ,  C12N15/1136 ,  C12N15/1138 ,  C12N15/8509 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53

Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.

Abstract translation: 公开了免疫原性Nogo受体-1多肽，Nogo受体-1抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白和编码其的核酸。 还公开了Nogo受体拮抗剂多核苷酸。 还公开了包含这样的Nogo受体抗体，其抗原结合片段，可溶性Nogo受体及其融合蛋白，编码相同的核苷酸和拮抗剂多核苷酸的制备和使用方法。

公开(公告)号：US20150344553A1

公开(公告)日：2015-12-03

申请号：US14654176

申请日：2013-12-20

Applicant: BIOGEN MA INC. ,  BIOGEN IDEC INTERNATIOANL NEUROSCIENCE GMBH

Inventor： Paul H. Weinreb ,  Feng Chen ,  Ellen A. Garber ,  Jan Grimm ,  Fable Montrasio

IPC: C07K16/18 ,  G01N33/68 ,  A61K49/00 ,  A61K49/16 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K45/06 ,  A61K49/00 ,  A61K49/16 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/6896 ,  G01N2333/47 ,  G01N2800/2814

Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.

公开(公告)号：US20190233530A1

公开(公告)日：2019-08-01

申请号：US16379844

申请日：2019-04-10

Applicant: UCB BIOPHARMA SPRL ,  BIOGEN MA INC.

Inventor： Linda C. Burkly ,  Janine L. Ferrant-Orgettas ,  Ellen A. Garber ,  Yen-Ming Hsu ,  Lihe Su ,  Frederick R. Taylor ,  Ralph Adams ,  Derek Thomas Brown ,  Andrew George Popplewell ,  Martyn Kim Robinson ,  Anthony Shock ,  Kerry Louise Tyson

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/2875 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

公开(公告)号：US20150315273A1

公开(公告)日：2015-11-05

申请号：US14677521

申请日：2015-04-02

Applicant: Biogen MA Inc.

Inventor： Sha Mi ,  R. Blake Pepinsky ,  Zhaohui Shao ,  Ellen A. Garber ,  Steven D. Miklasz ,  Christilyn Graff

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.

Abstract translation: 内源性Sp35是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节因子。 阻断内源性Sp35功能的分子，这种抗Sp35抗体可以用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供对Sp35特异性的抗体，以及使用抗体作为内源性Sp35功能拮抗剂的方法。 本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。 本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，其包括对需要这种治疗的脊椎动物施用有效量的抗Sp35抗体。

公开(公告)号：US09598484B2

公开(公告)日：2017-03-21

申请号：US14654176

申请日：2013-12-20

Applicant: Biogen MA Inc. ,  Biogen International Neuroscience GmbH

Inventor： Paul H. Weinreb ,  Feng Chen ,  Ellen A. Garber ,  Jan Grimm ,  Fabio Montrasio

IPC: C07K16/18 ,  A61K39/00 ,  G01N33/68 ,  A61K39/395 ,  A61K45/06 ,  A61K49/00 ,  A61K49/16

CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K45/06 ,  A61K49/00 ,  A61K49/16 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/6896 ,  G01N2333/47 ,  G01N2800/2814

Abstract: Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.